Notch Therapeutics

Dr. Gregory Block, Senior Vice President, Corporate Development 

Oct. 12 | 11:15am | Oxford Biomedica Ballroom 

Vancouver, Canada 


In-person Presentation 

Notch Therapeutics is a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived immunotherapies, with an initial focus on cancer where cell therapies offer transformational benefits over existing standards of care. Notch is working to maximize the benefit of cell therapies through a proprietary T cell-production platform which combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch’s iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design and manufacture a uniform and unlimited supply of therapeutic T cells. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions